You are here: Industry Insights > ArQule

News List

Merck closes $2.7bn acquisition of biopharmaceutical firm ArQule pharmaceutical-technology
January 19, 2020
Merck (MSD) has completed its previously announced acquisition of US-based biopharmaceutical company ArQule. The $2.7bn deal closed following completion of the cash tender offer that involved acquiring ArQule’s outstanding shares of common stock at $20 pe
How Merck's desire for more 'control' became a $2.7B ArQule buy fiercepharma
December 20, 2019
It’s not uncommon for partnership talks focused on one drug to escalate into a full-on buyout. And that's just what happened with Merck & Co.’s $2.7 billion deal for ArQule.
Merck to Acquire ArQule americanpharmaceuticalreview
December 12, 2019
Merck and ArQule announced the companies have entered into a definitive agreement under which Merck, through a subsidiary ...
Merck to Acquire ArQule for $2.7B ContractPharma
December 11, 2019
Diversifies oncology pipeline with expansion into targeted therapies that treat hematological malignancies.
Merck to acquire ArQule in $2.7bn deal pharmaceutical-technology
December 11, 2019
Merck (MSD) has signed a definitive agreement to acquire biopharmaceutical company ArQule for a total cash consideration of $2.7bn, or $20 per share.
ArQule Reports Fourth Quarter and Full Year 2017 Financial Results biospace
March 06, 2018
ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for the fourth quarter and full year of 2017.